Your browser doesn't support javascript.
loading
Difficult-to-treat (DTR) Pseudomonas aeruginosa harboring Verona-Integron metallo-ß-lactamase (blaVIM): infection management and molecular analysis.
Vega, Ana D; DeRonde, Kailynn; Jimenez, Adriana; Piazza, Michael; Vu, Christine; Martinez, Octavio; Rojas, Laura J; Marshall, Steven; Yasmin, Mohamad; Bonomo, Robert A; Abbo, Lilian M.
Affiliation
  • Vega AD; Department of Pharmacy, Jackson Health System, Miami, Florida, USA.
  • DeRonde K; Department of Pharmacy, Jackson Health System, Miami, Florida, USA.
  • Jimenez A; Department of Pharmacy, Jackson Health System, Miami, Florida, USA.
  • Piazza M; Department of Epidemiology, Florida International University, Miami, Florida, USA.
  • Vu C; Department of Medicine, Virtua Medical Group, Medford, New Jersey, USA.
  • Martinez O; Department of Pharmacy, Jackson Health System, Miami, Florida, USA.
  • Rojas LJ; Department of Pharmacy, Jackson Health System, Miami, Florida, USA.
  • Marshall S; Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Yasmin M; Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Bonomo RA; CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio, USA.
  • Abbo LM; Department of Medicine, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Antimicrob Agents Chemother ; 68(5): e0147423, 2024 May 02.
Article in En | MEDLINE | ID: mdl-38602418
ABSTRACT
Pseudomonas aeruginosa harboring Verona Integron-encoded metallo-ß-lactamase enzymes (VIM-CRPA) have been associated with infection outbreaks in several parts of the world. In the US, however, VIM-CRPA remain rare. Starting in December 2018, we identified a cluster of cases in our institution. Herein, we present our epidemiological investigation and strategies to control/manage these challenging infections. This study was conducted in a large academic healthcare system in Miami, FL, between December 2018 and January 2022. Patients were prospectively identified via rapid molecular diagnostics when cultures revealed carbapenem-resistant P. aeruginosa. Alerts were received in real time by the antimicrobial stewardship program and infection prevention teams. Upon alert recognition, a series of interventions were performed as a coordinated effort. A retrospective chart review was conducted to collect patient demographics, antimicrobial therapy, and clinical outcomes. Thirty-nine VIM-CRPA isolates led to infection in 21 patients. The majority were male (76.2%); the median age was 52 years. The majority were mechanically ventilated (n = 15/21; 71.4%); 47.6% (n = 10/21) received renal replacement therapy at the time of index culture. Respiratory (n = 20/39; 51.3%) or bloodstream (n = 13/39; 33.3%) were the most common sources. Most infections (n = 23/37; 62.2%) were treated with an aztreonam-avibactam regimen. Six patients (28.6%) expired within 30 days of index VIM-CRPA infection. Fourteen isolates were selected for whole genome sequencing. Most of them belonged to ST111 (12/14), and they all carried blaVIM-2 chromosomally. This report describes the clinical experience treating serious VIM-CRPA infections with either aztreonam-ceftazidime/avibactam or cefiderocol in combination with other agents. The importance of implementing infection prevention strategies to curb VIM-CRPA outbreaks is also demonstrated.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Pseudomonas aeruginosa / Pseudomonas Infections / Beta-Lactamases / Microbial Sensitivity Tests / Anti-Bacterial Agents Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Antimicrob Agents Chemother Year: 2024 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Pseudomonas aeruginosa / Pseudomonas Infections / Beta-Lactamases / Microbial Sensitivity Tests / Anti-Bacterial Agents Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Antimicrob Agents Chemother Year: 2024 Type: Article Affiliation country: United States